Headlines about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aurinia Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 44.9408297549363 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- Investors may need a consensus Analysts Rating: Aurinia Pharmaceuticals Inc. (AUPH) – Wall Street Morning (wallstreetmorning.com)
- Investors may need a consensus Analysts Rating: Aurinia … – Wall Street Morning (wallstreetmorning.com)
- Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Attention Seeking Stock – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) – The Investor Guide (wallstreetnews24.com)
- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) – Here’s What to Focus on – Nasdaq Journal (press release) (nasdaqjournal.com)
A number of research firms have weighed in on AUPH. Seaport Global Securities reissued a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. Vetr raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 target price on the stock in a report on Tuesday, September 19th. Leerink Swann boosted their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $14.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, October 23rd. Finally, Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.79.
Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) opened at $5.35 on Friday. Aurinia Pharmaceuticals has a 12 month low of $2.30 and a 12 month high of $10.54. The company has a market cap of $441.70, a price-to-earnings ratio of -4.05 and a beta of 2.35.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. equities analysts predict that Aurinia Pharmaceuticals will post -1.05 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2018/01/13/aurinia-pharmaceuticals-auph-given-news-sentiment-rating-of-0-19.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.